Price/Volume Alert in Novavax on Swine Flu Vaccine Data (NVAX)

Posted in pre-market 
August 18th, 2009

Novavax Inc. (NASDAQ: NVAX) is soaring on news that its experimental H1N1 swine flu vaccine was effective in animal tests.  The vaccine won’t be approved nor ready for commercial use in humans for two years.  At 8:53 AM EST we have already seen over 650,000 shares trade hands and th last print has the stock up 10.5% at $4.96. The 52-week high is $5.59 and average volume is now over 6 million shares now that swine flu is such a buzz-word for traders. -JON OGG

Comments are closed